Pharmaceuticals News and Research

RSS

Hospira's proposed generic injectables business acquisition: HSR review period expires

Hospira, Inc.,, the world leader in generic injectable pharmaceuticals, and Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, today announced that the Hart-Scott-Rodino (HSR) review period for Hospira's proposed acquisition of Orchid's generic injectable pharmaceuticals business has expired with no action by the Federal Trade Commission (FTC).

11 Feb 2010

Today's OpEds: Prescriptions for health reform

The best ideas out there are not those that were passed by the House and Senate last year, which consist of more spending, more regulations and more bureaucracy. If the president is serious about building a system that delivers more quality choices at lower cost for every American, here's where he should start (Newt Gingrich and John C. Goodman, 2/10).

11 Feb 2010

PLAN C Agency launches Hepatitis B awareness campaign in the West Coast

PLAN C Agency, in collaboration with biopharmaceutical company Gilead Sciences, launched a Hepatitis B awareness campaign titled "B HERE" at three college campuses in the West Coast. The goal was to raise the much needed awareness regarding the rising epidemic of Hepatitis B among Asian Americans and educate the youth on the importance of getting tested.

11 Feb 2010

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Amira Pharmaceuticals, Inc. announced today that their collaborators, Andrew Tager, M.D. and Flavia V. Castelino, M.D. of Massachusetts General Hospital, Harvard Medical School, will present a preclinical proof-of-concept study which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through its high affinity LPA1 receptor, is an important mediator of fibrogenesis in the bleomycin mouse model of scleroderma. Data will be presented as part of a poster session for the 1st Systemic Sclerosis World Congress to be held in Florence, Italy, February 11 to 13, 2010.

11 Feb 2010

Cambrex announces fourth-quarter financial results ended December 31, 2009

Cambrex Corporation reports fourth quarter results for the period ended December 31, 2009.

10 Feb 2010

BioMed Realty Trust announces financial results for fourth-quarter and full-year ended December 31, 2009

BioMed Realty Trust, Inc., a real estate investment trust focused on Providing Real Estate to the Life Science Industry®, today announced financial results for the fourth quarter and full-year ended December 31, 2009.

10 Feb 2010

Allylix raises $6M in first closing of Series C financing

Allylix Inc. announced today that it has raised $6 million in the first closing of its Series C financing. The money will allow the Company to commercialize its first three products for the food and fragrance industry, and allow it to advance several additional products in its pipeline.

10 Feb 2010

Trimel BioPharma Holdings updates business developments

Trimel BioPharma Holdings Inc. is today providing an update on a number of operational items that have contributed significantly to advancing the Company and achieving its initial objectives.

10 Feb 2010

AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA

AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).

10 Feb 2010

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to increasing competition from other biologic agents, Amgen/Pfizer/Takeda's Enbrel (etanercept)—the leading therapy in the psoriasis drug market in 2008—will account for less than one-fifth of sales in the overall market in 2018. In 2008, Enbrel garnered half of the psoriasis drug market share in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

10 Feb 2010

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Raptor Pharmaceutical Corp., today announced the presentation of cystinosis data at the Annual Lysosomal Disease Network WORLD Symposium 2010, being held February 10-12 in Miami, Florida. Biomarker data from a Phase IIb pilot study of Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") will be the subject of a poster titled, "Correlation of Plasma Cysteamine and WBC Cystine Levels at Steady State in Patients Treated with Cysteamine Bitartrate." The results will also be published in an upcoming issue of the journal Molecular Genetics and Metabolism.

10 Feb 2010

Model Metrics launches Pharma2GO sales force automation solution for pharma and life science industries

Model Metrics has launched Pharma2GO Spring '10, a comprehensive sales force automation solution specifically designed for the pharmaceutical and life science industries that extends the power of Salesforce CRM to mobile devices.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

MDS Inc., a leading provider of products and services to the global life sciences markets, today announced that it has signed agreements to divest its remaining MDS Pharma Services Early Stage business, which provides Discovery through Phase IIa clinical trial services to biotechnology and pharmaceutical companies, for $45 million and certain minority equity interests.

10 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Avrio Biopharmaceuticals receives Cal FDB approval to manufacture and ship pharmaceutical products

Avrio Biopharmaceuticals, LLC, a wholly-owned subsidiary of Irvine Pharmaceutical Services, Inc., received approval to manufacture and ship pharmaceutical products by the California Department of Public Health, Food and Drug Branch (Cal FDB), completing the organization's portfolio of product development services in support of its pharmaceutical, biopharmaceutical, and medical device clients.

10 Feb 2010

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Alexza Pharmaceuticals, Inc. announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato® loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.

10 Feb 2010

Kinexus Bioinformatics announces the commercial release of Protein Kinase Microarray

Kinexus Bioinformatics Corporation announced the commercial release of its novel Protein Kinase Microarray with 200 recombinant human protein kinases for screening. The microarray has wide utility including applications for drug target counter screening, to identify novel kinase substrates, establish kinase antibody specificities, and for the discovery and testing of protein kinase-protein and protein kinase-compound interactions.

10 Feb 2010

Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug

Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into a collaboration and license agreement with Alexza Pharmaceuticals, Inc.

10 Feb 2010

BioClinica reports financial results for quarter and year ended December 31, 2009

BioClinica™, Inc., a global provider of clinical trial services, today announced its financial results for the quarter and year ended December 31, 2009. The operating results of Phoenix Data Systems (“PDS”) are included in the financial results following the acquisition of PDS that was completed March 24, 2008.

From Clario 10 Feb 2010

Pharmaceuticals News and Research

Hospira's proposed generic injectables business acquisition: HSR review period expires

Today's OpEds: Prescriptions for health reform

PLAN C Agency launches Hepatitis B awareness campaign in the West Coast

Bioactive lipid LPA mediates fibrogenesis in bleomycin mouse model of scleroderma

Cambrex announces fourth-quarter financial results ended December 31, 2009

BioMed Realty Trust announces financial results for fourth-quarter and full-year ended December 31, 2009

Allylix raises $6M in first closing of Series C financing

Trimel BioPharma Holdings updates business developments

AVANIR Pharmaceuticals receives patent for low-dose quinidine formulations of Zenvia to treat PBA

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium

Model Metrics launches Pharma2GO sales force automation solution for pharma and life science industries

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Avrio Biopharmaceuticals receives Cal FDB approval to manufacture and ship pharmaceutical products

Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International

Kinexus Bioinformatics announces the commercial release of Protein Kinase Microarray

Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug

BioClinica reports financial results for quarter and year ended December 31, 2009

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence